Assessment of more than 400,000 people over the age of 40 demonstrates that homozygosity for a CCR5 variant that prevents HIV-1 infection comes at the cost of increased rates of mortality.
Change history
08 October 2019
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
References
Ryder, S. P. CRISPR J. 1, 355–357 (2018).
Gupta, R. K. et al. Nature 568, 244–248 (2019).
Wei, X. & Nielsen, R. Nat. Med. https://doi.org/10.1038/s41591-019-0459-6 (2019).
Keele, B. F. et al. Proc. Natl. Acad. Sci. USA 105, 7552–7557 (2008).
Samson, M. et al. Nature 382, 722–725 (1996).
Liu, R. et al. Cell 86, 367–377 (1996).
Stephens, J. C. et al. Am. J. Hum. Genet. 62, 1507–1515 (1998).
Hütter, G. et al. N. Engl. J. Med. 360, 692–698 (2009).
Hütter, G. N. Engl. J. Med. 371, 2437–2438 (2014).
Verheyen, J. et al. Clin. Infect. Dis. 68, 684–687 (2019).
Falcon, A. et al. J. Gen. Virol. 96, 2074–2078 (2015).
Bycroft, C. et al. Nature 562, 203–209 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Luban, J. The hidden cost of genetic resistance to HIV-1. Nat Med 25, 878–879 (2019). https://doi.org/10.1038/s41591-019-0481-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-019-0481-8
- Springer Nature America, Inc.